Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants

ClinicalTrials.gov ID: NCT02555878

Public ClinicalTrials.gov record NCT02555878. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of the primary composite outcome as defined by objectively confirmed symptomatic lower extremity proximal deep vein thrombosis (DVT), asymptomatic lower extremity proximal DVT, symptomatic lower extremity distal DVT, symptomatic upper extremity DVT, symptomatic non-fatal pulmonary embolism (PE), incidental PE, and venous thromboembolism (VTE)-related death in ambulatory adult participants with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE.

Study identification

NCT ID
NCT02555878
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
841 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 11, 2015 (Actual)
Primary completion
Aug 24, 2018 (Actual)
Completion
Aug 24, 2018 (Actual)
Last update posted
Sep 12, 2019

2015 – 2018

United States locations

U.S. sites
70
U.S. states
30
U.S. cities
70
Facility City State ZIP Site status
Not listed Phoenix Arizona — —
Not listed Tucson Arizona — —
Not listed Little Rock Arkansas — —
Not listed Los Angeles California — —
Not listed Martinez California — —
Not listed Santa Barbara California — —
Not listed Torrance California — —
Not listed Upland California — —
Not listed Denver Colorado — —
Not listed Norwich Connecticut — —
Not listed Gainesville Florida — —
Not listed Miami Florida — —
Not listed Miami Shores Florida — —
Not listed New Port Richey Florida — —
Not listed Atlanta Georgia — —
Not listed Evanston Illinois — —
Not listed Joliet Illinois — —
Not listed Peoria Illinois — —
Not listed Rockford Illinois — —
Not listed Skokie Illinois — —
Not listed Urbana Illinois — —
Not listed Anderson Indiana — —
Not listed Cedar Rapids Iowa — —
Not listed Brewer Maine — —
Not listed Baltimore Maryland — —
Not listed Silver Spring Maryland — —
Not listed Boston Massachusetts — —
Not listed Detroit Michigan — —
Not listed Rochester Minnesota — —
Not listed Saint Cloud Minnesota — —
Not listed Kansas City Missouri — —
Not listed Grand Island Nebraska — —
Not listed Las Vegas Nevada — —
Not listed Lebanon New Hampshire — —
Not listed Albany New York — —
Not listed East Syracuse New York — —
Not listed New York New York — —
Not listed Rochester New York — —
Not listed The Bronx New York — —
Not listed Charlotte North Carolina — —
Not listed High Point North Carolina — —
Not listed Cleveland Ohio — —
Not listed Eugene Oregon — —
Not listed Portland Oregon — —
Not listed Erie Pennsylvania — —
Not listed Charleston South Carolina — —
Not listed Greenville South Carolina — —
Not listed North Charleston South Carolina — —
Not listed Rapid City South Dakota — —
Not listed Nashville Tennessee — —
Not listed Abilene Texas — —
Not listed Austin Texas — —
Not listed Beaumont Texas — —
Not listed Bedford Texas — —
Not listed Dallas Texas — —
Not listed Denton Texas — —
Not listed Flower Mound Texas — —
Not listed Garland Texas — —
Not listed Houston Texas — —
Not listed Paris Texas — —
Not listed San Antonio Texas — —
Not listed Sugar Land Texas — —
Not listed Temple Texas — —
Not listed The Woodlands Texas — —
Not listed Tyler Texas — —
Not listed Waco Texas — —
Not listed Roanoke Virginia — —
Not listed Winchester Virginia — —
Not listed Green Bay Wisconsin — —
Not listed Weston Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02555878, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 12, 2019 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02555878 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →